GROWTH
Top line stable.
+16.0% YoY versus +16.9% prior. 3y CAGR +22.5%.
+16.0%
Novo Nordisk A/S NVO
Healthcare · Market Cap: $195.0B
Live price unavailable
Fundamentals as of 2026-03-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $195.0B
Live price unavailable
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
3 of 4 legendary models say BUY NVO — but Joel Greenblatt disagrees.
What would legendary investors pay for NVO?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — Novo Nordisk A/S's 60.7% ROE ranks above the S&P 500 median, and D/E 1.75 stays within healthy bounds.
Financial story
Yes — Novo Nordisk A/S's 60.7% ROE shows strong capital efficiency, and its 1.75 debt-to-equity stays within healthy bounds.
Bottom line: NVO is rated BUY by 3 of 4 legendary models, with 0 holding and 1 flagging it overvalued, but earns a B sector grade (63/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
+16.0% YoY versus +16.9% prior. 3y CAGR +22.5%.
+16.0%Net margin 33.1% versus 34.8% prior (−1.6pp). Operating 43.7%.
33.1%P/E 10.1x — 70% below the 5y median of 33.2x. Forward 2.0x hints at EPS expansion next year.
10.1x3 of 4 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
NVO's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
NVO is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
3 of 4 legendary investor models rate NVO a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $710. See the per-investor fair-value table in the valuation tab.
NVO trades at 10.8x earnings. Sector context and per-investor signals are in the valuation tab.
How does NVO compare?
See exactly where NVO ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingNVO sits at #12 in Healthcare with a B grade (63/100).
